Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension

British Journal of Ophthalmology

Volumn 90, Issue 11, 2006, Pages 1370-1373

  Cantor, L B ^a,b   Hoop, J ^b   Morgan, L ^b   WuDunn, D ^b   Catoira, Y ^b   Bournias, Thomas ^c   Cantor, Louis ^b   Dirks, Monte ^d   Duzman, Efraim ^e   Mansouri, Arash ^f   Mundorf, Thomas ^g   Simmons, Steven ^h   Williams, Robert ⁱ  

^a INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d Black Hills Regional Eye Institute   (United States)

^e Lakeside Vision Center   (United States)

^f Access Eye Centers   (United States)

^g Mundorf Eye Center   (United States)

^h Glaucoma Consultants of the Capital Region   (United States)

ⁱ Taustine Eye Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIMATOPROST; TRAVOPROST;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; GLAUCOMA; HUMAN; HYPEREMIA; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; AMIDES; ANTIHYPERTENSIVE AGENTS; CHI-SQUARE DISTRIBUTION; CLOPROSTENOL; FEMALE; FOLLOW-UP STUDIES; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; LIPIDS; MALE; MIDDLE AGED; OCULAR HYPERTENSION; TREATMENT OUTCOME;

EID: 33750716516     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2006.094326     Document Type: Article

References (12)

1. Heijl A, Leske C, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Arch Ophthalmol 2002;120:1268-79.
2. Higginbotham E, Schuman J, Goldberg l, et al. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol 2002;120:1286-93.
3. Noecker RJ, Dirks MS, Choplin NT, et al. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol 2003;135:55-63.
4. Gandolfi S, Simmons ST, Sturm R, et al. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther 2001;18:110-21.
5. Simmons ST, Dirks MS, Noecker RJ. Bimatoprost versus latanoprost in lowering intraocular pressure in glaucoma and ocular hypertension: results from parallel-group comparison trials. Adv Ther 2004;21:247-62.
6. Brubaker RF. Mechanism of action of bimatoprost (Lumigan™). Surv Ophthalmol 2001;45(Suppl 4):S347-51.
7. Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001;132:472-84.
8. Orengo-Nania S, Landry T, Von Tress M, et al. Evaluation of travoprost as adjunctive therapy in patients with uncontrolled intraocular pressure while using timolol 0.5%. Am J Ophthalmol 2001;132:860-8.
9. Parrish RK, Palmberg P, Sheu WP, et al. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 2003;135:688-703.
10. American Academy of Ophthalmology. American Academy of Ophthalmology preferred practice pattern: primary open-angle glaucoma. San Francisco: American Academy of Ophthalmology, 2000.
11. Noecker RJ, Earl ML, Mundorf T, et al. Bimatoprost 0.03% versus travoprost 0.004% in black Americans with glaucoma or ocular hypertension. Adv Ther 2003;20:121-8.
12. Rollins J. Doctor-patient communication in US glaucoma patients: The Glaucoma Research Foundation Patient Survey. Rockville, MD: ARVO, 2004.